Short answer
OPKO HEALTH, INC. (OPK) filed its Q2 2026 10-Q quarterly report on Jul 27, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $164M (up 4.3% year over year) with net income of −$8M.
Q2 2026 key financials · XBRL
- Revenue
- $164M
- +4.3% YoY · +31.7% QoQ
- Net income
- −$8M
- +94.3% YoY · +84.7% QoQ
- Operating margin
- -4.3%
- Gross margin
- 48.9%
- EPS (diluted)
- −$0.01
- +95.2% YoY · +85.7% QoQ
Source: XBRL data from the OPKO HEALTH, INC. (OPK) Q2 2026 10-Q on SEC EDGAR. USD.
OPKO HEALTH, INC. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No material risk-factor changes from the 10-K; previously disclosed risks carried forward
- Liquidity risk: $451.716 million contractual obligations, including $246.854 million due thereafter under 2044 Royalty Financing
- Regulatory and legal risk: funding needs depend on clinical-trial outcomes, regulatory approvals, government investigations, and ITA litigation
- Operational risk: near-term cash requirements depend on Rayaldee success and partners’ Mazdutide launch
- Foreign-exchange risk: 33.3% of six-month revenue denominated outside USD, primarily Chilean Peso and Euro exposures
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other OPKO HEALTH, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.